These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 11367508)
1. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Kiener PA; Davis PM; Murray JL; Youssef S; Rankin BM; Kowala M Int Immunopharmacol; 2001 Jan; 1(1):105-18. PubMed ID: 11367508 [TBL] [Abstract][Full Text] [Related]
2. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Wagner AH; Gebauer M; Güldenzoph B; Hecker M Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205 [TBL] [Abstract][Full Text] [Related]
3. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Perchellet JP; Perchellet EM; Crow KR; Buszek KR; Brown N; Ellappan S; Gao G; Luo D; Minatoya M; Lushington GH Int J Mol Med; 2009 Nov; 24(5):633-43. PubMed ID: 19787197 [TBL] [Abstract][Full Text] [Related]
4. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. Okopień B; Krysiak R; Kowalski J; Madej A; Belowski D; Zieliński M; Herman ZS J Cardiovasc Pharmacol; 2005 Sep; 46(3):377-86. PubMed ID: 16116345 [TBL] [Abstract][Full Text] [Related]
5. Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. Porreca E; Di Febbo C; Baccante G; Di Nisio M; Cuccurullo F J Am Coll Cardiol; 2002 Jun; 39(11):1752-7. PubMed ID: 12039487 [TBL] [Abstract][Full Text] [Related]
6. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. Takahashi HK; Mori S; Iwagaki H; Yoshino T; Tanaka N; Weitz-Schmidt G; Nishibori M J Leukoc Biol; 2005 Mar; 77(3):400-7. PubMed ID: 15618295 [TBL] [Abstract][Full Text] [Related]
7. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Grip O; Janciauskiene S; Lindgren S Eur J Pharmacol; 2000 Dec; 410(1):83-92. PubMed ID: 11134659 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Romano M; Diomede L; Sironi M; Massimiliano L; Sottocorno M; Polentarutti N; Guglielmotti A; Albani D; Bruno A; Fruscella P; Salmona M; Vecchi A; Pinza M; Mantovani A Lab Invest; 2000 Jul; 80(7):1095-100. PubMed ID: 10908155 [TBL] [Abstract][Full Text] [Related]
10. Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells. McFarland AJ; Davey AK; Anoopkumar-Dukie S Mediators Inflamm; 2017; 2017():2582745. PubMed ID: 28546657 [TBL] [Abstract][Full Text] [Related]
11. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Ni W; Egashira K; Kataoka C; Kitamoto S; Koyanagi M; Inoue S; Takeshita A Circ Res; 2001 Aug; 89(5):415-21. PubMed ID: 11532902 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Knapp AC; Huang J; Starling G; Kiener PA Atherosclerosis; 2000 Sep; 152(1):217-27. PubMed ID: 10996358 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
14. Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction. Takahashi HK; Iwagaki H; Yagi T; Kanke T; Liu K; Yoshino T; Tanaka N; Nishibori M Clin Immunol; 2007 Jun; 123(3):324-32. PubMed ID: 17482516 [TBL] [Abstract][Full Text] [Related]
15. Differences in statin associated neuroprotection corresponds with either decreased production of IL-1β or TNF-α in an in vitro model of neuroinflammation-induced neurodegeneration. McFarland AJ; Davey AK; McDermott CM; Grant GD; Lewohl J; Anoopkumar-Dukie S Toxicol Appl Pharmacol; 2018 Apr; 344():56-73. PubMed ID: 29522792 [TBL] [Abstract][Full Text] [Related]
16. Immunotropic Effects and Proposed Mechanism of Action for 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors (Statins). Arefieva TI; Filatova AY; Potekhina AV; Shchinova AM Biochemistry (Mosc); 2018 Aug; 83(8):874-889. PubMed ID: 30208827 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of HMG-CoA Reductase: Current and Future Prospects. Singh N; Tamariz J; Chamorro G; Medina-Franco JL Mini Rev Med Chem; 2009 Oct; 9(11):1272-83. PubMed ID: 19929805 [TBL] [Abstract][Full Text] [Related]
19. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells. Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930 [TBL] [Abstract][Full Text] [Related]
20. Modulation of the inflammatory process by statins. Crisby M Timely Top Med Cardiovasc Dis; 2005 Mar; 9():E3. PubMed ID: 15824762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]